Hormonal contraception and hiv-1 infection: Medroxyprogesterone acetate suppresses innate and adaptive immune mechanisms

Endocrinology

Volumn 154, Issue 3, 2013, Pages 1282-1295

  Huijbregts, Richard P H ^a   Helton, E Scott ^a   Michel, Katherine G ^a   Sabbaj, Steffanie ^a,c,d   Richter, Holly E ^b   Goepfert, Paul A ^a,c,d   Hel, Zdenek ^a,d  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c University of Alabama at Birmingham   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CHEMOKINE; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MEDROXYPROGESTERONE ACETATE; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; C57BL 6 MOUSE; CELL CULTURE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HORMONAL CONTRACEPTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; INNATE IMMUNITY; LYMPHOCYTE PROLIFERATION; MOUSE; MUCOSA CELL; NONHUMAN; NORMAL HUMAN; ORAL CONTRACEPTION; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMACYTOID DENDRITIC CELL; PREMENOPAUSE; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; T LYMPHOCYTE; VAGINA MUCOSA; VIRUS REPLICATION;

ADAPTIVE IMMUNITY; ADULT; ANIMALS; CHEMOKINES; CONTRACEPTIVE AGENTS, FEMALE; CYTOKINES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, INNATE; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE ACTIVATION; MEDROXYPROGESTERONE ACETATE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; RECEPTORS, CCR5; RECEPTORS, CXCR4; T-LYMPHOCYTES; VAGINA; VIRUS REPLICATION; YOUNG ADULT;

EID: 84874607828     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2012-1850     Document Type: Article

References (110)

1. World Health Organization. Hormonal Contraception and HIV. Technical Statement. Geneva, Switzerland: World Health Organization; 2012.
2. Affandi B. Injectable contraceptives: A worldwide perspective. J Fam Plann Reprod Health Care. 2002;28:3-4.
3. FHI 360. Expanding Access to Injectable Contraception. Durham, NC: FHI 360; 2012.
4. Hel Z, Stringer E, Mestecky J. Sex steroid hormones, hormonal contraception, and the immunobiology of human immunodeficiency virus-1 infection. Endocr Rev. 2010;31:79-97.
5. Ungchusak K, Rehle T, Thammapornpilap P, Spiegelman D, Brinkmann U, Siraprapasiri T. Determinants of HIV infection among female commercial sex workers in northeastern Thailand: Results from a longitudinal study. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;12:500-507.
6. Wand H, Ramjee G. The effects of injectable hormonal contraceptives on HIV seroconversion and on sexually transmitted infections. AIDS. 2012;26:375-380.
7. Morrison CS, Chen PL, Kwok C, et al. Hormonal contraception and HIV acquisition: Reanalysis using marginal structural modeling. AIDS. 2010;24:1778-1781.
8. Heffron R, Donnell D, Rees H, et al. Use of hormonal contraceptives and risk of HIV-1 transmission: A prospective cohort study. Lancet Infect Dis. 2012;12:19-26.
9. Baeten JM, Benki S, Chohan V, et al. Hormonal contraceptive use, herpes simplex virus infection, and risk of HIV-1 acquisition among Kenyan women. AIDS. 2007;21:1771-1777.
10. Kumwenda NI, Kumwenda J, Kafulafula G, et al. HIV-1 incidence among women of reproductive age in Malawi. Int J STD AIDS. 2008;19:339-341.
11. Plummer FA, Simonsen JN, CameronDW,et al. Cofactors in malefemale sexual transmission of human immunodeficiency virus type 1. J Infect Dis. 1991;163:233-239.
12. Heffron R, Rees H, Mugo N, Baeten JM. Use of hormonal contraceptives and risk of HIV-1 transmission. Lancet Infect Dis. 2012;12:510-511.
13. Lavreys L, Baeten JM, Kreiss JK, et al. Injectable contraceptive use and genital ulcer disease during the early phase of HIV-1 infection increase plasma virus load in women. J Infect Dis. 2004;189:303-311.
14. Baeten JM, Lavreys L, Sagar M, et al. Effect of contraceptive methods on natural history of HIV: Studies from the Mombasa cohort. J Acquir Immune Defic Syndr. 2005;38(Suppl 1):S18-S21.
15. Stringer EM, Kaseba C, Levy J, et al. A randomized trial of the intrauterine contraceptive device vs hormonal contraception in women who are infected with the human immunodeficiency virus. Am J Obstet Gynecol. 2007;197:144-148.
16. Mostad SB, Overbaugh J, DeVange DM, et al. Hormonal contraception, vitamin A deficiency, and other risk factors for shedding of HIV-1 infected cells from the cervix and vagina. Lancet. 1997; 350:922-927.
17. Wang CC, McClelland RS, Overbaugh J, et al. The effect of hormonal contraception on genital tract shedding of HIV-1. AIDS. 2004;18:205-209.
18. Morrison CS, Bright P, Wong EL, et al. Hormonal contraceptive use, cervical ectopy, and the acquisition of cervical infections. Sex Transm Dis. 2004;31:561-567.
19. Baeten JM, Nyange PM, Richardson BA, et al. Hormonal contraception and risk of sexually transmitted disease acquisition: Results from a prospective study. Am J Obstet Gynecol. 2001;185:380-385.
20. Lavreys L, Chohan V, Overbaugh J, et al. Hormonal contraception and risk of cervical infections among HIV-1-seropositive Kenyan women. AIDS. 2004;18:2179-2184.
21. Hancock EB, Manhart LE, Nelson SJ, Kerani R, Wroblewski JK, Totten PA. Comprehensive assessment of sociodemographic and behavioral risk factors for Mycoplasma genitalium infection in women. Sex Transm Dis. 2010;37:777-783.
22. Abel K, Rourke T, Lu D, Bost K, McChesney MB, Miller CJ. Abrogation of attenuated lentivirus-induced protection in rhesus macaques by administration of Depo-Provera before intravaginal challenge with simian immunodeficiency virus mac239. J Infect Dis. 2004;190:1697-1705.
23. Genesca M, Li J, Fritts L, et al. Depo-Provera abrogates attenuated lentivirus-induced protection in male rhesus macaques challenged intravenously with pathogenic SIVmac239. J Med Primatol. 2007; 36:266-275.
24. Trunova N, Tsai L, Tung S, et al. Progestin-based contraceptive suppresses cellular immune responses in SHIV-infected rhesus macaques. Virology. 2006;352:169-177.
25. Veazey RS, Shattock RJ, Pope M, et al. Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med. 2003;9:343-346.
26. Kiddugavu M, Makumbi F, Wawer MJ, et al. Hormonal contraceptive use and HIV-1 infection in a population-based cohort in Rakai, Uganda. AIDS. 2003;17:233-240.
27. Myer L, Denny L, Wright TC, Kuhn L. Prospective study of hormonal contraception and women's risk of HIV infection in South Africa. Int J Epidemiol. 2007;36:166-174.
28. Kleinschmidt I, Rees H, Delany S, et al. Injectable progestin contraceptive use and risk of HIV infection in a South African family planning cohort. Contraception. 2007;75:461-467.
29. Reid SE, Dai JY, Wang J, et al. Pregnancy, contraceptive use, and HIV acquisition in HPTN 039: Relevance for HIV prevention trials among African women. J Acquir Immune Defic Syndr. 2010;53: 606-613.
30. StringerEM,GigantiM,Carter RJ, El-SadrW,Abrams EJ, Stringer JS. Hormonal contraception and HIV disease progression: A multicountry cohort analysis of the MTCT-Plus Initiative. AIDS 2009; 23(Suppl 1):S69-S77.
31. Bulterys M, Smith D, Chao A, Jaffe H. Hormonal contraception and incident HIV-1 infection: New insight and continuing challenges. AIDS. 2007;21:97-99.
32. Morrison CS. Hormonal contraception and HIV acquisition: Current evidence and ongoing research needs. Int J Epidemiol. 2007; 36:175-177.
33. Morrison CS, Richardson BA, Mmiro F, et al. Hormonal contraception and the risk of HIV acquisition. AIDS. 2007;21:85-95.
34. Shelton J. Scientists and the media must give a balanced view. Nature. 2011;479:7.
35. Gray RH. Use of hormonal contraceptives and risk of HIV-1 transmission. Lancet Infect Dis. 2012;12:507; author reply 510-511.
36. Koubovec D, Ronacher K, Stubsrud E, Louw A, Hapgood JP. Synthetic progestins used inHRThave different glucocorticoid agonist properties. Mol Cell Endocrinol. 2005;242:23-32.
37. Africander D, Verhoog N, Hapgood JP. Molecular mechanisms of steroid receptor-mediated actions by synthetic progestins used in HRT and contraception. Steroids. 2011;76:636-652.
38. Kontula K, Paavonen T, Luukkainen T, Andersson LC. Binding of progestins to the glucocorticoid receptor. Correlation to their glucocorticoid-like effects on in vitro functions of human mononuclear leukocytes. Biochem Pharmacol. 1983;32:1511-1518.
39. Palmieri D, Halverson DO, Ouatas T, et al. Medroxyprogesterone acetate elevation of Nm23-H1 metastasis suppressor expression in hormone receptor-negative breast cancer. J Natl Cancer Inst. 2005; 97:632-642.
40. Thomas CP, Liu KZ, Vats HS Medroxyprogesterone acetate binds the glucocorticoid receptor to stimulate α-ENaC and sgk1 expression in renal collecting duct epithelia. Am J Physiol Renal Physiol. 2006;290:F306-F312.
41. Rodriguez M, Reeves M, Caughey A. Evaluating the competing risks of HIV acquisition and maternal mortality in Africa: A decision analysis. BJOG. 2012;119:1067-1073.
42. Bamberger CM, Else T, Bamberger AM, Beil FU, Schulte HM. Dissociative glucocorticoid activity of medroxyprogesterone acetate in normal human lymphocytes. J Clin Endocrinol Metab. 1999;84:4055-4061.
43. Koubovec D, Vanden Berghe W, Vermeulen L, Haegeman G, Hapgood JP. Medroxyprogesterone acetate downregulates cytokine gene expression in mouse fibroblast cells. Mol Cell Endocrinol. 2004;221:75-85.
44. Kleynhans L, Du Plessis N, Black GF, et al. Medroxyprogesterone acetate alters Mycobacterium bovis BCG-induced cytokine production in peripheral blood mononuclear cells of contraceptive users. PLoS One. 2011;6:e24639.
45. Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Strober W. Current Protocols in Immunology. New York: John Wiley & Sons; 1991-2012.
46. Edmonds TG, Ding H, Yuan X, et al. Replication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMC. Virology. 2010;408:1-13.
47. Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology. 1990;1:43-46.
48. Perneger TV. What's wrong with Bonferroni adjustments. BMJ. 1998;316:1236-1238.
49. Berghofer B, Frommer T, Haley G, Fink L, Bein G, Hackstein H. TLR7 ligands induce higher IFN-γ production in females. J Immunol. 2006;177:2088-2096.
50. Meier A, Chang JJ, Chan ES, et al. Sex differences in the Toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1. Nat Med. 2009;15:955-959.
51. Hughes GC, Thomas S, Li C, Kaja MK, Clark EA. Cutting edge: Progesterone regulates IFN-γ production by plasmacytoid dendritic cells. J Immunol. 2008;180:2029-2033.
52. Siegal FP, Kadowaki N, ShodellM,et al. The nature of the principal type 1 interferon-producing cells in human blood. Science. 1999; 284:1835-1837.
53. Gilliet M, Cao W, Liu YJ. Plasmacytoid dendritic cells: Sensing nucleic acids in viral infection and autoimmune diseases. Nat Rev Immunol. 2008;8:594-606.
54. Prakash M, Kapembwa MS, Gotch F, Patterson S. Oral contraceptive use induces upregulation of the CCR5 chemokine receptor on CD4-T cells in the cervical epithelium of healthy women. J Reprod Immunol. 2002;54:117-131.
55. Sheffield JS, WendelGDJr, McIntire DD, Norgard MV. The effect of progesterone levels and pregnancy on HIV-1 coreceptor expression. Reprod Sci. 2009;16:20-31.
56. Signoret N, Oldridge J, Pelchen-Matthews A, et al. Phorbol esters and SDF-1 induce rapid endocytosis and down modulation of the chemokine receptor CXCR4. J Cell Biol. 1997;139:651-664.
57. Signoret N, Rosenkilde MM, Klasse PJ, et al. Differential regulation of CXCR4 and CCR5 endocytosis. J Cell Sci. 1998;111(Pt 18):2819-2830.
58. Asin SN, HeimbergAM,Eszterhas SK, Rollenhagen C, Howell AL. Estradiol and progesterone regulate HIV type 1 replication in peripheral blood cells. AIDS Res Hum Retroviruses. 2008;24:701-716.
59. Markham PD, Salahuddin SZ, Popovic M, et al. Advances in the isolation of HTLV-III from patients with AIDS and AIDS-related complex and from donors at risk. Cancer Res. 1985;45:4588s-4591s.
60. Markham PD, Salahuddin SZ, Veren K, Orndorff S, Gallo RC. Hydrocortisone and some other hormones enhance the expression of HTLV-III. Int J Cancer. 1986;37:67-72.
61. Soudeyns H, Geleziunas R, Shyamala G, Hiscott J, Wainberg MA. Identification of a novel glucocorticoid response element within the genome of the human immunodeficiency virus type 1. Virology. 1993;194:758-768.
62. Soudeyns H, Wainberg MA. Effects of RU486 on HIV-1 replication. Nat Med. 1997;3:1302-1303.
63. Li Q, Estes JD, Schlievert PM, et al. Glycerol monolaurate prevents mucosal SIV transmission. Nature. 2009;458:1034-1038.
64. Kirton KT, Cornette JC. Return of ovulatory cyclicity following an intramuscular injection of medroxyprogesterone acetate (Provera). Contraception. 1974;10:39-45.
65. Shrimanker K, Saxena BN, Fotherby K. A radioimmunoassay for serum medroxyprogesterone acetate. J Steroid Biochem. 1978;9: 359-363.
66. Ortiz A, Hirol M, Stanczyk FZ, Goebelsmann U, Mishell DR. Serum medroxyprogesterone acetate (MPA) concentrations and ovarian function following intramuscular injection of depo-MPA. J Clin Endocrinol Metab. 1977;44:32-38.
67. Nanda K, Amaral E, Hays M, Viscola MA, Mehta N, Bahamondes L. Pharmacokinetic interactions between depot medroxyprogesterone acetate and combination antiretroviral therapy. Fertil Steril. 2008;90:965-971.
68. McKay LI, Cidlowski JA. Molecular control of immune/inflammatory responses: Interactions between nuclear factor-K B and steroid receptor-signaling pathways. Endocr Rev. 1999;20:435-459.
69. De Bosscher K, Vanden Berghe W, Haegeman G. The interplay between the glucocorticoid receptor and nuclear factor-K B or activator protein-1: Molecular mechanisms for gene repression. Endocr Rev. 2003;24:488-522.
70. Smoak KA, Cidlowski JA. Mechanisms of glucocorticoid receptor signaling during inflammation. Mech Ageing Dev. 2004;125:697-706.
71. Rogatsky I, Luecke HF, Leitman DC, Yamamoto KR. Alternate surfaces of transcriptional coregulator GRIP1 function in different glucocorticoid receptor activation and repression contexts. Proc Natl Acad Sci U S A. 2002;99:16701-16706.
72. Hapgood JP, Tomasicchio M. Modulation of HIV-1 virulence via the host glucocorticoid receptor: Towards further understanding the molecular mechanisms of HIV-1 pathogenesis. Arch Virol. 2010;155:1009-1019.
73. Liberman AC, Refojo D, Druker J, et al. The activated glucocorticoid receptor inhibits the transcription factor T-bet by direct protein-protein interaction. FASEB J. 2007;21:1177-1188.
74. Maneechotesuwan K, Yao X, Ito K,et al. Suppression of GATA-3 nuclear import and phosphorylation: A novel mechanism of corticosteroid action in allergic disease. PLoS Med. 2009;6:e1000076.
75. Kino T, De Martino MU, Charmandari E, Mirani M, Chrousos GP. Tissue glucocorticoid resistance/hypersensitivity syndromes. J Steroid Biochem Mol Biol. 2003;85:457-467.
76. Mirani M, Elenkov I, Volpi S, Hiroi N, Chrousos GP, Kino T. HIV-1 protein Vpr suppresses IL-12 production from human monocytes by enhancing glucocorticoid action: Potential implications of Vpr coactivator activity for the innate and cellular immunity deficits observed in HIV-1 infection. J Immunol. 2002;169: 6361-6368.
77. Borel IM, Freire SM, Rivera E, Canellada A, Binaghi RA, Margni RA. Modulation of the immune response by progesterone-induced lymphocyte factors. Scand. J Immunol. 1999;49:244-250.
78. Cherpes TL, Busch JL, Sheridan BS, Harvey SA, Hendricks RL. Medroxyprogesterone acetate inhibits CD8+ T cell viral-specific effector function and induces herpes simplex virus type 1 reactivation. J Immunol. 2008;181:969-975.
79. Clemens LE, Siiteri PK, Stites DP. Mechanism of immunosuppression of progesterone on maternal lymphocyte activation during pregnancy. J Immunol. 1979;122:1978-1985.
80. Laskarin G, Strbo N, Sotosek V, et al. Progesterone directly and indirectly affects perforin expression in cytolytic cells.AmJ Reprod Immunol. 1999;42:312-320.
81. Mannel DN, Falk W, Yron I. Inhibition of murine cytotoxic T cell responses by progesterone. Immunol Lett. 1990;26:89-94.
82. Mori T, Kobayashi H, Nishimoto H, Suzuki A, Nishimura T. Inhibitory effect of progesterone and 20α-hydroxypregn-4-en-3-one on the phytohemagglutinin-induced transformation of human lymphocytes. Am J Obstet Gynecol. 1977;127:151-157.
83. Pavia C, Siiteri PK, Perlman JD, Stites DP. Suppression of murine allogeneic cell interactions by sex hormones. J Reprod Immunol. 1979;1:33-38.
84. Szekeres-Bartho J, Hadnagy J, Pacsa AS. The suppressive effect of progesterone on lymphocyte cytotoxicity: Unique progesterone sensitivity of pregnancy lymphocytes. J Reprod Immunol. 1985; 7:121-128.
85. Wyle FA, Kent Jr. Immunosuppression by sex steroid hormones. The effect upon PHA-and PPD-stimulated lymphocytes. Clin Exp Immunol. 1977;27:407-415.
86. Enomoto LM, Kloberdanz KJ, Mack DG, Elizabeth D, Weinberg A. Ex vivo effect of estrogen and progesterone compared with dexamethasone on cell-mediated immunity of HIV-infected and uninfected subjects. J Acquir Immune Defic Syndr. 2007;45:137-143
87. Gillgrass AE, Ashkar AA, Rosenthal KL, Kaushic C. Prolonged exposure to progesterone prevents induction of protective mucosal responses following intravaginal immunization with attenuated herpes simplex virus type 2. J Virol. 2003;77:9845-9851.
88. PiccinniMP,GiudiziMG,Biagiotti R, et al. Progesterone favors the development of human T helper cells producing Th2-type cytokines and promotes both IL-4 production and membrane CD30 expression in established Th1 cell clones. J Immunol. 1995;155: 128-133.
89. Piccinni MP, Maggi E, Romagnani S. Role of hormone-controlled T-cell cytokines in the maintenance of pregnancy. Biochem Soc Trans. 2000;28:212-215.
90. Szekeres-Bartho J, Barakonyi A, Par G, Polgar B, Palkovics T, Szereday L. Progesterone as an immunomodulatory molecule. Int Immunopharmacol. 2001;1:1037-1048.
91. Szekeres-Bartho J, Faust Z, Varga P. The expression of a progesterone-induced immunomodulatory protein in pregnancy lymphocytes. Am J Reprod Immunol. 1995;34:342-348.
92. Szekeres-Bartho J, Wegmann TG. A progesterone-dependent immunomodulatory protein alters the Th1/Th2 balance. J Reprod Immunol. 1996;31:81-95.
93. Szereday L, Varga P, Szekeres-Bartho J. Cytokine production by lymphocytes in pregnancy. Am J Reprod Immunol. 1997;38:418-422.
94. StraubRH.The complex role of estrogens in inflammation. Endocr Rev. 2007;28:521-574.
95. Zang YC, Halder JB, Hong J, Rivera VM, Zhang JZ. Regulatory effects of estriol onTcell migration and cytokine profile: Inhibition of transcription factor NF-K B. J Neuroimmunol. 2002;124:106-114.
96. Salem ML, Hossain MS, Nomoto K. Mediation of the immunomodulatory effect of α-estradiol on inflammatory responses by inhibition of recruitment and activation of inflammatory cells and their gene expression of TNF-α and IFN-γ. Int Arch Allergy Immunol. 2000;121:235-245.
97. Ito A, Buenafe AC, Matejuk A, et al. Estrogen inhibits systemic T cell expression of TNF-α and recruitment of TNF-α-T cells and macrophages into the CNS of mice developing experimental encephalomyelitis. Clin Immunol. 2002;102:275-282.
98. Bermejo M, Martin-Serrano J, Oberlin E, et al. Activation of blood T lymphocytes down-regulates CXCR4 expression and interferes with propagation of X4 HIV strains. Eur J Immunol. 1998;28: 3192-3204.
99. Venkatesan S, Rose JJ, Lodge R, Murphy PM, Foley JF. Distinct mechanisms of agonist-induced endocytosis for human chemokine receptors CCR5 and CXCR4. Mol Biol Cell. 2003;14:3305-3324.
100. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P. Identification of RANTES, MIP-1β, and MIP-1β as the major HIV-suppressive factors produced by CD8+ T cells. Science. 1995; 270:1811-1815.
101. Vicenzi E, Alfano M, Ghezzi S, et al. Divergent regulation of HIV-1 replication in PBMC of infected individuals by CC chemokines: Suppression by RANTES, MIP-1β, and MCP-3, and enhancement by MCP-1. J Leukoc Biol. 2000;68:405-412.
102. Signoret N, Christophe T, Oppermann M, Marsh M. pH-independent endocytic cycling of the chemokine receptor CCR5. Traffic. 2004;5:529-543.
103. Signoret N, Pelchen-Matthews A, Mack M, Proudfoot AE, Marsh M. Endocytosis and recycling of the HIV coreceptor CCR5. J Cell Biol. 2000;151:1281-1294.
104. Wu L, Paxton WA, Kassam N, et al. CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro. J Exp Med. 1997;185:1681-1691.
105. Ghosh D. Glucocorticoid receptor-binding site in the human immunodeficiency virus long terminal repeat. J Virol. 1992;66:586-590.
106. Kolesnitchenko V, Snart RS. Regulatory elements in the human immunodeficiency virus type 1 long terminal repeat LTR (HIV-1) responsive to steroid hormone stimulation. AIDS Res Hum Retroviruses. 1992;8:1977-1980.
107. Wiegers K, Schwarck D, Reimer R, Bohn W. Activation of the glucocorticoid receptor releases unstimulated PBMCs from an early block in HIV-1 replication. Virology. 2008;375:73-84.
108. Clemetson DB, Moss GB, Willerford DM, et al. Detection of HIV DNA in cervical and vaginal secretions. Prevalence and correlates among women in Nairobi, Kenya. JAMA. 1993;269:2860-2864.
109. Kaushic C, Ashkar AA, Reid LA, Rosenthal KL. Progesterone increases susceptibility and decreases immune responses to genital herpes infection. J Virol. 2003;77:4558-4565.
110. Jain AK. Hormonal contraception and HIV acquisition risk: Implications for individual users and public policies. Contraception. 2012;86:645-652.